Related Experiment Video
Updated: Aug 8, 2026
05:13
Development of Combinatorial Therapeutics for Spinal Cord Injury using Stem Cell Delivery
Published on: June 7, 2024
Injectable Supramolecular Hydrogel Encapsulating CRISPR-Engineered MSCs Drives Synergistic Neuroprotection and
Chao Xu1, Yi Liu2, Mengge Wang1
1Institute of Advanced Biotechnology, Institute of Homeostatic Medicine, and School of Medicine, Southern University of Science and Technology, Shenzhen, China.
Advanced Healthcare Materials
|August 7, 2026
Summary
This study developed a novel hydrogel combined with gene-edited stem cells to treat traumatic brain injury (TBI). The engineered cells and hydrogel significantly improved outcomes in a TBI mouse model, offering new hope for CNS injury therapies.
Area of Science:
- Biomaterials Science
- Neuroscience
- Regenerative Medicine
Background:
- Traumatic brain injury (TBI) causes complex secondary pathologies with limited treatment options.
- Mesenchymal stem cell (MSC) transplantation shows promise for TBI but is hindered by poor cell survival and retention.
- Existing therapies struggle to address the multifaceted nature of TBI recovery.
Purpose of the Study:
- To engineer an advanced cell therapy platform for TBI by combining a novel hydrogel with genetically modified stem cells.
- To enhance the viability, retention, and therapeutic efficacy of stem cells in the context of TBI.
- To investigate the potential of CRISPR-edited stem cells within a biomimetic hydrogel for promoting neural repair.
Main Methods:
- Development of an injectable, self-healing supramolecular gelatin hydrogel (iGel).
- Engineering of "Super MSCs" (SPMSCs) using CRISPR-SAM to express neuroprotective factors IL-10 and FGF21.
- Encapsulation of SPMSCs within iGel and evaluation in a murine TBI model.
Main Results:
- The iGel hydrogel significantly improved SPMSC viability and sustained neuroprotective factor secretion.
- iGel-SPMSC treatment demonstrated potent immunomodulatory effects, reducing neuroinflammation and apoptosis.
- Significant improvements were observed in blood-brain barrier integrity, angiogenesis, neurogenesis, and functional recovery (sensorimotor and memory).
- Reduced cerebral edema and lesion volume were noted in treated mice.
Conclusions:
- A versatile, gene-editing-empowered biomaterial platform effectively overcomes critical limitations in cell therapy for CNS injuries.
- The combinatorial iGel and SPMSC approach represents a promising strategy for TBI treatment.
- This platform has broad potential for treating various central nervous system injuries.
